Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69


ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.

Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB.

Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29.


Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.


Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, Kasman I, Zhang Y, Dennis MS, Eastham-Anderson J, Jubb AM, Hwang O, Desai R, Schmidt M, Nannini MA, Barck KH, Carano RA, Forrest WF, Song Q, Chen DS, Naumovski L, Singh M, Ye W, Hegde PS.

J Clin Invest. 2013 Sep;123(9):3997-4009. doi: 10.1172/JCI67892. Epub 2013 Aug 15.


Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC.

Leuk Lymphoma. 2009 Dec;50(12):1977-82. doi: 10.3109/10428190903288464.


The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.

Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI.

Clin Cancer Res. 2009 Oct 15;15(20):6462-71. doi: 10.1158/1078-0432.CCR-09-0905. Epub 2009 Oct 13.


Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds.

Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC, Bailey AS, Fleming WH, Corless C, Felsher DW, Naumovski L, Lopez CD.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4390-5. doi: 10.1073/pnas.0809080106. Epub 2009 Feb 26.


Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression.

Wang Z, Lecane PS, Thiemann P, Fan Q, Cortez C, Ma X, Tonev D, Miles D, Naumovski L, Miller RA, Magda D, Cho DG, Sessler JL, Pike BL, Yeligar SM, Karaman MW, Hacia JG.

Mol Cancer. 2007 Jan 19;6:9.


Tumor localization and antitumor efficacy of novel sapphyrin compounds.

Naumovski L, Sirisawad M, Lecane P, Chen J, Ramos J, Wang Z, Cortez C, Magda D, Thiemann P, Boswell G, Miles D, Cho DG, Sessler JL, Miller R.

Mol Cancer Ther. 2006 Nov;5(11):2798-805.


Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities.

Evans JP, Xu F, Sirisawad M, Miller R, Naumovski L, de Montellano PR.

Mol Pharmacol. 2007 Jan;71(1):193-200. Epub 2006 Oct 3.


Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation.

Ramos J, Sirisawad M, Miller R, Naumovski L.

Mol Cancer Ther. 2006 May;5(5):1176-82.


New polyethyleneglycol-functionalized texaphyrins: synthesis and in vitro biological studies.

Wei WH, Wang Z, Mizuno T, Cortez C, Fu L, Sirisawad M, Naumovski L, Magda D, Sessler JL.

Dalton Trans. 2006 Apr 28;(16):1934-42. Epub 2006 Jan 24.


Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.

Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, Magda D.

Cancer Res. 2005 Dec 15;65(24):11676-88.


A practical guideline for calculating parenteral nutrition cycles.

Longhurst C, Naumovski L, Garcia-Careaga M, Kerner J.

Nutr Clin Pract. 2003 Dec;18(6):517-20.


Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis.

Chen J, Ramos J, Sirisawad M, Miller R, Naumovski L.

Apoptosis. 2005 Oct;10(5):1131-42.


Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.

Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, Yu Z, Chen D, Naumovski L, Lopez CD.

J Biol Chem. 2005 Oct 14;280(41):34473-80. Epub 2005 Aug 9.


Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.

Naumovski L, Ramos J, Sirisawad M, Chen J, Thiemann P, Lecane P, Magda D, Wang Z, Cortez C, Boswell G, Gyu Cho D, Sessler J, Miller R.

Mol Cancer Ther. 2005 Jun;4(6):968-76.


ARMER, apoptotic regulator in the membrane of the endoplasmic reticulum, a novel inhibitor of apoptosis.

Lui HM, Chen J, Wang L, Naumovski L.

Mol Cancer Res. 2003 May;1(7):508-18.


Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.

Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK.

Oncogene. 2002 Nov 7;21(51):7901-11.


Inhibition of cell death by ribosomal protein L35a.

Lopez CD, Martinovsky G, Naumovski L.

Cancer Lett. 2002 Jun 28;180(2):195-202.


Intracellular redistribution of interferon-inducible proteins Nmi and IFP 35 in apoptotic cells.

Chen J, Naumovski L.

J Interferon Cytokine Res. 2002 Feb;22(2):237-43.


ASPP proteins specifically stimulate the apoptotic function of p53.

Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X.

Mol Cell. 2001 Oct;8(4):781-94.


Two-hybrid interactions confirmed by coimmunoprecipitation of epitope-tagged clones.

Naumovski L.

Methods Mol Biol. 2001;177:151-9. No abstract available.


Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V.

Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW.

J Nucl Med. 2001 Feb;42(2):309-16.


Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53.

Lopez CD, Ao Y, Rohde LH, Perez TD, O'Connor DJ, Lu X, Ford JM, Naumovski L.

Mol Cell Biol. 2000 Nov;20(21):8018-25.


Interferon-inducible Myc/STAT-interacting protein Nmi associates with IFP 35 into a high molecular mass complex and inhibits proteasome-mediated degradation of IFP 35.

Chen J, Shpall RL, Meyerdierks A, Hagemeier M, Böttger EC, Naumovski L.

J Biol Chem. 2000 Nov 17;275(46):36278-84.


Interferon-alpha induces nmi-IFP35 heterodimeric complex formation that is affected by the phosphorylation of IFP35.

Zhou X, Liao J, Meyerdierks A, Feng L, Naumovski L, Bottger EC, Omary MB.

J Biol Chem. 2000 Jul 14;275(28):21364-71.


Subcellular localization of interferon-inducible Myc/stat-interacting protein Nmi is regulated by a novel IFP 35 homologous domain.

Lee ND, Chen J, Shpall RL, Naumovski L.

J Interferon Cytokine Res. 1999 Nov;19(11):1245-52.


Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice.

Smith KS, Rhee JW, Naumovski L, Cleary ML.

Mol Cell Biol. 1999 Jun;19(6):4443-51.


Endothelial cell apoptosis in capillary network remodeling.

Pollman MJ, Naumovski L, Gibbons GH.

J Cell Physiol. 1999 Mar;178(3):359-70.


Imaging of apoptosis (programmed cell death) with 99mTc annexin V.

Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Strauss HW.

J Nucl Med. 1999 Jan;40(1):184-91.


Interferon-induced upregulation and cytoplasmic localization of Myc-interacting protein Nmi.

Lebrun SJ, Shpall RL, Naumovski L.

J Interferon Cytokine Res. 1998 Sep;18(9):767-71.


In vivo detection and imaging of phosphatidylserine expression during programmed cell death.

Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Darkes M, Robbins RC, Maecker HT, Strauss HW.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6349-54.


BCL-2 expression does not not correlate with patient outcome in pediatric acute myelogenous leukemia.

Naumovski L, Martinovsky G, Wong C, Chang M, Ravendranath Y, Weinstein H, Dahl G.

Leuk Res. 1998 Jan;22(1):81-7.


Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy.

Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF.

Blood. 1997 May 15;89(10):3778-86.


Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy.

Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D.

Blood. 1996 Mar 1;87(5):1951-6.


Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients.

Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM.

Antimicrob Agents Chemother. 1992 Sep;36(9):1991-6. Erratum in: Antimicrob Agents Chemother 1993 Feb;37(2):375.


Treatment of thrombotic thrombocytopenic purpura with cryosupernatant.

Naumovski L, Pillsbury HE.

Am J Hematol. 1991 Nov;38(3):250-1. No abstract available.


Ingestion of a laryngoscope light bulb during delivery room resuscitation.

Naumovski L, Schaffer K, Fleisher B.

Pediatrics. 1991 Apr;87(4):581-2. No abstract available.


Purification and characterization of Rad3 ATPase/DNA helicase from Saccharomyces cerevisiae.

Harosh I, Naumovski L, Friedberg EC.

J Biol Chem. 1989 Dec 5;264(34):20532-9.


SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma.

Naumovski L, Utz PJ, Bergstrom SK, Morgan R, Molina A, Toole JJ, Glader BE, McFall P, Weiss LM, Warnke R, et al.

Blood. 1989 Dec;74(8):2733-42.

Supplemental Content

Loading ...
Support Center